This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Cellink | |
|---|---|
| Name | Cellink |
| Type | Public |
| Founded | 2016 |
| Founders | Henriksson, Bergström |
| Headquarters | Gothenburg, Sweden |
| Industry | Biotechnology |
| Products | Bioprinting systems, bioinks, laboratory consumables |
| Revenue | (public company) |
| Website | (company homepage) |
Cellink
Cellink is a biotechnology company founded in 2016 that developed and commercialized bioprinting platforms, specialized bioinks, and laboratory instruments for life-science research. The company became known for translating additive manufacturing methods into tissue engineering workflows, supplying tools used in organ-on-chip studies, regenerative-medicine research, and pharmaceutical testing. Over a short period it expanded globally through product launches, acquisitions, and partnerships with academic institutions, contract research organizations, and life-science corporations.
The company was established by entrepreneurs from Gothenburg who combined expertise in biomaterials, engineering, and entrepreneurship to create an open-platform bioprinter. Early milestones included the launch of a first-generation desktop bioprinter and chemically defined bioinks that targeted academic labs and biotechnology startups. Rapid growth involved listings on financial markets and strategic acquisitions in North America and Europe, positioning the firm alongside established suppliers such as Thermo Fisher Scientific, Merck Group, and GE Healthcare in supplying laboratory automation and life-science consumables. Its timeline intersected with advances at institutions like Harvard University, Massachusetts Institute of Technology, and Karolinska Institutet, where bioprinting methods were being explored for vascularized tissues and organoid assembly. Leadership changes and investor rounds reflected shifting priorities between research-focused product development and broader commercial distribution across regions including United States, China, and Japan.
The product portfolio emphasized extrusion-based and inkjet-based bioprinters, modular hardware, and a catalog of cell-compatible hydrogels branded as bioinks. Devices were designed to integrate with incubators from Thermo Fisher Scientific and imaging systems from Zeiss and Leica Microsystems for live-cell monitoring. Bioinks included gelatin-methacryloyl formulations and alginate blends compatible with primary cells from sources such as ATCC and clinical isolates used in translational projects at hospitals like Karolinska University Hospital. Accessories spanned microfluidic chips compatible with organ-on-chip platforms developed by groups at Wyss Institute and consumables used in workflows alongside instruments from Agilent Technologies and PerkinElmer. Software suites enabled G-code generation and printer calibration, aiming for interoperability with laboratory information management systems employed at institutions including Pfizer and Novartis.
Researchers used the company’s systems for engineering cartilage, skin models, and vascular networks in preclinical studies at universities including University of California, San Francisco, Johns Hopkins University, and University of Oxford. Applications extended to oncology, where tumor microenvironments were modeled in collaboration with cancer centers such as Dana–Farber Cancer Institute and Memorial Sloan Kettering Cancer Center for drug screening. Regenerative-medicine groups at Mayo Clinic and Cleveland Clinic investigated scaffold-guided tissue repair and cell delivery strategies. In toxicology and pharmacology, contract research organizations like Charles River Laboratories and Covance incorporated bioprinted tissues into ADME and safety assessment pipelines. Publications in journals including Nature Communications, Advanced Materials, and Biomaterials showcased methods for co-culture patterning, perfusable constructs, and organoid integration.
As a publicly traded enterprise, the company pursued growth through product diversification, regional distribution agreements, and acquisitions of niche technology providers in bioprinting and laboratory automation. Corporate activities involved collaborations with venture investors and strategic partners from the life-science supply chain, including distributors in United States, Germany, and China. Commercial strategy targeted universities, biotechnology firms, and pharmaceutical companies such as Roche and Johnson & Johnson for adoption of in vitro human-relevant models. Human-resources initiatives and internal R&D centers paralleled expansion into service offerings, including contract bioprinting and custom bioink formulation for industrial customers.
The deployment of bioprinting technologies intersected with regulatory frameworks overseen by agencies like European Medicines Agency, U.S. Food and Drug Administration, and national health authorities in Asia. Ethical discussions involved oversight from institutional review boards at hospitals and universities, debates on 3D-printed human tissues raised in conferences hosted by organizations such as The Hastings Center and International Society for Stem Cell Research. Concerns over reproducibility, biobanking provenance tied to institutions like Biobank Sweden and patient-consent standards at clinical sites informed company policies on material sourcing and data governance. Standards bodies including ISO and consortia active with ASTM International influenced guidance for characterization, sterility, and safety testing of bioprinted constructs.
The company established research partnerships with academic laboratories at Karolinska Institutet, Uppsala University, and Chalmers University of Technology, and commercial collaborations with suppliers such as Sigma-Aldrich and instrument vendors like Hamilton Company. Collaborative projects with pharmaceutical firms including AstraZeneca and biotechnology companies fostered application-specific workflows for lead identification and toxicity testing. Cross-sector consortia with organ-on-chip developers at MIMETAS and translational networks at Innovative Medicines Initiative supported standardization efforts and multi-site validation studies.
Its innovations received attention from industry awards and technology showcases in biotechnology and additive manufacturing sectors, featuring at exhibitions organized by BIO International Convention and Formnext. Recognition included entrepreneurship prizes at Swedish innovation forums and nominations in categories by trade publications such as Nature Biotechnology and Lab Manager. Peer-reviewed methodological papers and citations in reviews on bioprinting technologies further established its visibility among research communities at institutions like Imperial College London and ETH Zurich.
Category:Biotechnology companies